DrMedHealth: What the FDA Letter Means for What You Pay

Violations were identified and documented during a review of DrMedHealth’s website, https://drmedhealth.com, FDA Establishment Identifier (FEI) 3044020737, in March 2026. FDA observed that your website offers compounded drug products, including semaglutide and tirzepatide products.

1. 1

   “1. The following claims concerning compounded semaglutide and tirzepatide products appear on your website:”

2. 2

   ““Same active ingredient as Ozempic®””

3. 3

   ““Same active ingredient as Mounjaro®””

4. 4

   “Compounded drug products are not FDA-approved. Your claims represent that the compounded drug products you offer have been FDA-approved or otherwise evaluated for safety and effectiveness when they have not.”

1. 1

   Letter issued

   June 2026

2. 2

   15-working-day response window

   FDA gives the company 15 working days to respond in writing.

3. 3

   Close-out, if issued

   FDA may post one once it is satisfied the cited issues have been corrected.

drmedhealth.com returned a live storefront on 2026-08-09 titled "GLP-1 Medical Weight Loss | Semaglutide & Tirzepatide | Dr. Medical Health", describing itself in its own copy as "an affordable, fast LegitScript-certified GLP-1 medical weight loss telehealth platform" and running a free-assessment intake, with MedicalBusiness structured data on the homepage. That is a check of whether the site is up and what it says about itself; the certification claim was not independently verified here and is recorded as the site's own wording.

The wording FDA chose here is worth more than the ad copy it was aimed at. Through the 2025 wave the agency's conclusion was that claims like these "imply that your products are the same as an FDA-approved product" — an argument about chemistry, which a determined shopper can at least try to reason about. By June 2026 the sentence had changed: the claims "represent that the compounded drug products you offer have been FDA-approved or otherwise evaluated for safety and effectiveness when they have not." That is an argument about REVIEW, and it is the thing a price cannot tell you. "Same active ingredient as Ozempic®" is, taken literally, a statement about a molecule; what it lands as is a statement that somebody checked. Nobody did — that is what compounded means, and it is the entire distance between the two prices being compared. The practical habit is to read the registered-trademark symbol as the tell rather than the reassurance: the ® belongs to the approved product, and its presence in the sentence is precisely the borrowed credibility the letter is about. This page's own storefront advertises a third-party certification, which is a separate thing again — a certification is a vendor screening, not an FDA approval, and neither one is a finding about what is in the vial. FDA made no finding here about the drug's quality or contents.

As of August 2026, FDA’s public tracking for this letter does not show a logged company response. Companies are not required to make a response public, and FDA does not always update this field promptly — this is not evidence DrMedHealth failed to respond.